Top FDA Official Appointed By Trump Admin Departs After Three Months
Newsweek6 days
Prasad's departure represents a victory against regulatory overreach that threatened patient access to life-saving treatments. His decision to halt Elevidys shipments ignored desperate families fighting Duchenne muscular dystrophy and demonstrated dangerous government interference in medical decisions. The Wall Street Journal correctly identified this as regulatory "mugging" that chills pharmaceutical innovation.
Prasad's hadresignation toshows gohow becausepharmaceutical anylobbying officialand whopolitical prioritizespressure politicalcan ideologyundermine overlegitimate patientsafety accessconcerns mustat bethe held accountableFDA. His decisionevidence-based approach to haltdrug aapprovals life-savingand genewillingness therapyto forquestion dyingtreatments childrenwith showedquestionable callousefficacy disregardrepresented forexactly familiesthe desperatekind forof treatments.scientific Thisrigor regulatorythe overreachagency workedneeds. towardThe destroyingcoordinated Presidentattack Trump'sagainst pro-patienthim agendaprioritized andindustry Rightprofits toover Trypatient principlessafety.
Prasad's resignationhad showsto howgo pharmaceuticalbecause lobbyingany andofficial who prioritizes political pressureideology canover underminepatient legitimateaccess safetymust concernsbe atheld the FDAaccountable. His evidence-baseddecision approach to drughalt approvalsa andlife-saving willingnessgene totherapy questionfor treatmentsdying withchildren questionableshowed efficacycallous representeddisregard exactlyfor thefamilies kinddesperate offor scientifictreatments. rigorThis theregulatory agencyoverreach needs.worked Thetoward coordinateddestroying attackPresident againstTrump's himpro-patient prioritizedagenda industryand profitsRight overto patientTry safetyprinciples.
Prasad's resignationhad exposesto dangerousgo politicalbecause interferenceany inofficial scientificwho decision-makingprioritizes atpolitical theideology FDA.over Althoughpatient heaccess alignsmust withbe right-wingheld skepticismaccountable. ofHis vaccines,decision Prasadto washalt stilla forcedlife-saving outgene aftertherapy makingfor evidence-baseddying safetychildren decisionsshowed aboutcallous adisregard treatmentfor linkedfamilies todesperate patientfor deathstreatments. IndustryThis lobbyingregulatory andoverreach activistworked pressuretoward seemdestroying toPresident beTrump's overridingpro-patient legitimateagenda regulatoryand concernsRight aboutto drugTry safetyprinciples.
Prasad's resignation exposes dangerous political interference in scientific decision-making at the FDA. Although he aligns with right-wing skepticism of vaccines, Prasad was still forced out after making evidence-based safety decisions about a treatment linked to patient deaths. Industry lobbying and activist pressure seem to be overriding legitimate regulatory concerns about drug safety.